“OTREXUP provides an attractive new option that may benefit patients who have had an inadequate response to or are intolerant of oral MTX,” said Paul K. Wotton, PhD, President and Chief Executive ...

EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NAS: ATRS) today announced that data from a pivotal clinical trial of OTREXUP™ (methotrexate) for subcutaneous injection were selected for live, ...

OTREXUP (methotrexate) for subcutaneous injection Antares Pharma announced the availability of Otrexup (methotrexate for subcutaneous injection) for once-weekly self-administration with a single-dose ...

EWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the divestiture of OTREXUP ® (methotrexate) ...

LAKE FOREST, Ill., March 31, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT) and BlinkRx, the leading patient access solution, today announced a collaboration to support ...

Antares Pharma didn't impress the market with its Q1 results, but a pending Food and Drug Administration decision on Otrexup might be a game changer for this small biotech. Results Antares reported a ...

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued ...

Antares ( ATRS) is preparing to launch Otrexup in January 2014; it is the first product it has ever introduced and investor attention is keenly focused on the launch. This report is not a ...

EWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the divestiture of OTREXUP® (methotrexate) ...

Antares Pharma announced its first-quarter results Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading. Here are the highlights from the company's results.